Ua hoʻolaha ʻo Brand Institute i kāna hui kūleʻa me Global Blood Therapeutics (GBT) i ka inoa ʻana i kā lākou EMA-approved therapy, OXBRYTA, i hōʻike ʻia no ka mālama ʻana i ka anemia hemolytic ma muli o ka sickle cell maʻi (SCD) i nā poʻe maʻi makua a me nā keiki maʻi he 12 mau makahiki a ʻoi aku. monotherapy a i hui pū ʻia me ka hydroxycarbamide (hydroxyurea). Hoʻopili kēia i ka ʻae ʻana o FDA a me Health Canada i ka lāʻau lapaʻau ma 2019.
"Ke hoʻomaikaʻi aku nei ka hui holoʻokoʻa o Brand Institute a me Drug Safety Institute i ka Global Blood Therapeutics no ka ʻae ʻana o FDA iā OXBRYTA," wahi a ka Luna Hoʻokele a me Luna Nui o Brand Institute, ʻo James L. Dettore. "He hiki ke hoʻololi i kēia lāʻau hoʻololi i ka poʻe ma ʻEulopa e noho nei me kēia maʻi hoʻonāwaliwali."
ʻO OXBRYTA ka lāʻau lapaʻau mua i ʻae ʻia ma ʻEulopa e hoʻopaʻa pololei i ka sickle hemoglobin (HbS) polymerization, ka molecular kumu o ka sickling a me ka luku ʻana i nā ʻāpana koko ʻulaʻula ma SCD. Hana ʻo OXBRYTA ma ka hoʻonui ʻana i ka pilina o ka hemoglobin no ka oxygen. No ka mea, ʻaʻole polymerize ka hemoglobin sickle oxygenated, ʻaʻole ʻo OXBRYTA i ka polymerization sickle hemoglobin a me ka hopena o ka sickling a me ka luku ʻana i nā ʻāpana koko ʻulaʻula.
"Ke manaʻoʻiʻo nei mākou he kūpono maikaʻi ka inoa OXBRYTA no ka huahana," hoʻomau ʻo Dettore. "Ma kahi o ka suffix pili 'oxygen', e pili ana i ke ʻano o ka hana o ka huahana, he nui nā ʻano a me nā ʻano a mākou e ʻimi nei i ka inoa i ka wā e kūkulu ai i kahi inoa inoa lāʻau lapaʻau hou."
He aha e lawe ʻia mai kēia ʻatikala:
- Brand Institute announced its successful partnership with Global Blood Therapeutics (GBT) in naming their EMA-approved therapy, OXBRYTA, indicated for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea).
- OXBRYTA is the first medicine approved in Europe that directly inhibits sickle hemoglobin (HbS) polymerization, the molecular basis of sickling and destruction of red blood cells in SCD.
- Since oxygenated sickle hemoglobin does not polymerize, OXBRYTA inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells.
